Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Yang Shi
Boston Children's Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Constellation Pharmaceuticals, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Shi’s NIH funded research involves studying LSD1 in pediatric glioblastoma and in tumor immunity. Constellation Pharmaceuticals aims to develop drugs targeting histone modifying enzymes and reader proteins to ultimately treat human diseases, with a focus on cancer. Constellation has recently started a drug discovery program on LSD1. Although Dr. Shi’s proposed research aims and the Company’s activity do not overlap, the outcome of the research may have the potential to indirectly benefit the company.
Epigenetic regulation of cellular plasticity and cancer cell fate
Project Narrative Acute myeloid leukemia (AML) and gliomas both display abnormal organization of DNA, which contributes to their rapid growth and inability to differentiate into mature, non-dividing blood or brain cells, respectively. Our goals are to understand how DNA organization influences cellular decisions between growth vs. differentiation into mature cell types. We will use a combination of genetic- and chemical-based assays and animal cancer models, to identify genes that contribute to the changes in DNA organization leading to excessive cell growth in AML and gliomas, and we will explore ways of targeting these genes therapeutically.
Filed on August 29, 2017.
Tell us what you know about Yang Shi's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Yang Shi filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Yang Shi | Children's Hospital Corporation | Conflict of Interest | Constellation Pharmaceuticals | $450,000 - $499,999 |
| Yang Shi | Boston Children's Hospital | Conflict of Interest | Constellation Pharmaceuticals, Inc. | $0 - $4,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.